The Production of Ac-225

Author(s): Jonathan W. Engle*

Journal Name: Current Radiopharmaceuticals

Volume 11 , Issue 3 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The radionuclide 225Ac and its daughter 213Bi are among the most interesting alpha emitters being evaluated for incorporation into targeted therapeutic vectors. Global supply of 225Ac is presently insufficient to meet anticipated clinical demand, but the deficiency has been targeted by many research and development efforts, privately and publicly funded. From more than a decade of these endeavors, no single production technology has emerged as a complete solution. In the foreseeable future, global supply of 225Ac will continue to be sourced from a patchwork of production methods and laboratories with a range of radioisotopic purities and achievable yields.

Objective and Conclusion: This manuscript attempts to present an overview of availability sources of 225Ac and production methods by which additional supplies might be made available to the community of clinical researchers seeking their application in the treatment of human disease.

Keywords: Ac-225, Ac-227, Bi-213, alpha-emitter, targeted radiotherapy, radionuclide production, review.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 21 October, 2018
Page: [173 - 179]
Pages: 7
DOI: 10.2174/1874471011666180418141357
Price: $65

Article Metrics

PDF: 51
PRC: 1